ArticleResearch and practice in thrombosis and haemostasis2025
Factor XI levels and the risk of cardiovascular events: a systematic review and meta-analysis of case-control and cohort studies.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The relationship between coagulation factor (F)XI and the risk of cardiovascular events has been investigated in several epidemiological studies, but the overall results remain inconclusive. Objectives: The aim of this systematic review and meta-analysis of case-control and cohort studies was to evaluate the relationship between FXI and the risk of cardiovascular events. FXI levels in the general population and the risk of different cardiovascular events were the primary exposure and outcome, respectively. Methods: Two independent reviewers (Li and Ma) screened all available literature to identify studies that met the inclusion criteria. A random or fixed-effects model was used, and heterogeneity was quantitatively tested by the Results: A total of 16 original studies were included in the quantitative meta-analysis. The meta-analysis results of both case-control and cohort studies showed a positive correlation between FXI levels and the risk of cardiovascular events (odds ratio [OR], 1.77; 95% CI, 1.17-2.68; hazard ratio [HR], 1.34; 95% CI, 1.09-1.64). Subgroup analysis revealed a positive correlation between FXI levels and the risk of myocardial infarction (OR, 1.63; 95% CI, 1.02-2.60; HR, 2.53; 95% CI, 1.15-5.60), while there was no significant correlation between FXI levels and acute coronary syndrome or ischemic stroke (OR, 1.78; 95% CI, 0.40-7.82; HR, 1.15; 95% CI, 0.93-1.41). Conclusion: Our findings support a positive correlation between FXI levels and the risk of cardiovascular events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.